Smoking Clinical Trial
Official title:
Imaging the Neurochemistry of Drug Addiction With PET
The investigators' project has two overarching goals. 1) The investigators will use newly developed positron emission tomography (PET) technology to investigate the dopaminergic neurochemistry of drugs of abuse including marijuana, traditional cigarettes, and cocaine, and 2) The investigators will extend PET technology to an additional neurotransmitter system - namely, the opioid-ergic system, using the same drugs of abuse.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - General Inclusion Criteria: 1. Men and women, aged 18-55 years 2. Able to read and write English and give voluntary written informed consent 3. Not treatment seeking or using treatment medications Tobacco Smokers 1. Have a Fagerström Test for Nicotine Dependence (FTND) rating of at least 3. 2. Have been using at least 7 cigarettes per day for at least 1 year 3. Carbon monoxide levels > 10 ppm during intake evaluation 4. Urine cotinine levels of > 150 ng/mL during intake evaluation 5. Are not current users of marijuana or other illicit drugs Marijuana Smokers 1. Meet DSM-V criteria for cannabis use disorder based on the structured clinical interview diagnostic (SCID) or regular cannabis use of >5 times/week 2. Test positive for THC 3. Have been smoking cannabis on a regular basis for > 1 year Cocaine Users 1. DSM-V criteria for Cocaine Abuse or Dependence 2. Recent street cocaine use in excess of amounts to be administered in the current study 3. Intravenous and/or smoked (crack/ freebase) use 4. Positive urine toxicology screen for cocaine Exclusion Criteria: - 1. Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology. 2. History of or current neurological or significant psychiatric disorder such as schizophrenia or bipolar disorder (DSM-IV Axis 1). 3. History of significant head trauma. 4. Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD). 5. Regular or current significant use of any prescription, herbal or illegal psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, ecstasy) in the past 6 mo, with no current illegal drug use confirmed by urine toxicology (except for cocaine and marijuana when relevant). 6. Significant substance misuse (including alcohol, and excluding cannabis and marijuana when relevant) that in the PI's determination interferes with the study results or safety of the subject. 7. Have MRI-incompatible implants and other contraindications for MRI, such as a pacemaker, artificial joints, non-removable body piercings, claustrophobia, etc. 8. Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year. 9. Subjects with current, past or anticipated exposure to radiation in the work place within one year of proposed research PET scans. 10. Subjects with history of IV drug use which would prevent venous access for PET tracer injection. |
Country | Name | City | State |
---|---|---|---|
United States | Connecticut Mental Health Center | New Haven | Connecticut |
United States | Yale Magnetic Resonance Research Center | New Haven | Connecticut |
United States | Yale PET Center | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in dopamine levels at baseline and after drug of dependence administration as confirmed by PET images. | PET images will be obtained in dependent subjects at baseline and after drug of dependence administration. Change in DA levels will be determined by change in binding potential of raclopride. | 90 minute PET scan acquisition. Drug of dependence will be given at -35 mins | |
Primary | Change in beta endorphin levels at baseline and after drug of dependence administration as confirmed by PET images. | PET images will be obtained in dependent subjects at baseline and after drug of dependence administration. Change in beta endorphin levels will be determined by change in binding potential of carfentanil. | 120 minute PET scan acquisition. Drug of dependence will be given at -35 mins |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02649556 -
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
|
N/A | |
Completed |
NCT03901066 -
Smoking Dependence and Periodontitis
|
||
Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT03305978 -
Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
|
N/A | |
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT06105424 -
BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability
|
N/A | |
Active, not recruiting |
NCT02752022 -
Monitoring the Transition From Smoking to E-cigarettes
|
||
Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
Completed |
NCT04340830 -
The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants
|
N/A | |
Completed |
NCT02912000 -
TEACH: Technology Evaluation to Address Child Health
|
N/A | |
Completed |
NCT02901171 -
The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation
|
N/A | |
Completed |
NCT02949648 -
Electronic Cigarette Use and Quitting in Youth
|
N/A | |
Completed |
NCT02246114 -
Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women
|
N/A | |
Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
Completed |
NCT01954407 -
Young Adults' Responses to Anti-smoking Messages
|
N/A | |
Completed |
NCT02008292 -
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
|
N/A | |
Completed |
NCT03448900 -
Intervention Study for Smoking Cessation in Spanish College Students
|
N/A |